When was Proteovant Therapeutics founded?

Proteovant Therapeutics was founded in 2021.

Where is Proteovant Therapeutics located?

Proteovant Therapeutics is headquartered in King Of Prussia, United States.

Who is the current CEO of Proteovant Therapeutics?

Drew Fromkin of Proteovant Therapeutics.

How many employees does Proteovant Therapeutics have?

As of Jul 01, 2024, the latest employee count at Proteovant Therapeutics is 38.

Is Proteovant Therapeutics a funded company?

Proteovant Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round.

How much is Proteovant Therapeutics worth?

The last known valuation of Proteovant Therapeutics was $***** as of Jun 30, 2023.

Where does Proteovant Therapeutics rank among its competitors?

Proteovant Therapeutics ranks 1710th amongst 2484 active competitors, of which 864 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Erasca, which secured $45M in Mar, 2024.

Who are the top competitors of Proteovant Therapeutics?

Proteovant Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Among them, Erasca secured the most recent funding round in March, 2024.

Proteovant Therapeutics - 2026 Company Profile, Team & Competitors

Q: Is Proteovant Therapeutics an acquired company?

Proteovant Therapeutics got acquired by SK on Jun 30, 2023.

Company Details

Developer of targeted protein degrader therapies for cancer and hematology. It has an AI-based targeted protein degradation platform that uses the human body's innate cellular machinery by the ubiquitin-proteasome system to identify and mark disease-causing proteins for destruction.

Website: www.proteovant.com
Email ID: *****@proteovant.com

Key Metrics

Founded Year

2021

Location

King Of Prussia, United States

Stage

Acquired

Last Known Valuation

$***** as on Jun 30, 2023

Ranked

1710^th among 2484 active competitors

Employee Count

38 as on Jul 01, 2024

Similar Companies

MiNA Therapeutics & 101 more

Exit Details

Acquired by SK (Jun 30, 2023)

View Proteovant Therapeutics' full profile

Proteovant Therapeutics got acquired by SK on Jun 30, 2023 at an acquisition amount of $47.5M.

Click here to take a look at Proteovant Therapeutics's acquisition in detail

Proteovant Therapeutics has not raised any funding rounds yet.

Proteovant Therapeutics' employee count trend

Proteovant Therapeutics has 38 employees as of Jul 24. Here is Proteovant Therapeutics's employee count trend over the years:

Employee count trend for Proteovant Therapeutics

Uncover Proteovant Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proteovant Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and C4 Therapeutics. Here is the list of Top 10 competitors of Proteovant Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, F-Prime Capital & 17 others	75/100
3rd	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
4th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	RA Capital Management, BB Biotech & 14 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
8th	Harbour BioMed 2016, Shanghai (China), Public	Developer of antibody therapeutics in immunology and oncology disease	$313M	Hudson Bay Capital, GIC & 19 others	71/100
9th	iTeos Therapeutics 2011, Cambridge (United States), Acquired	Developer of immunotherapy for treating cancer	$204M	Boxer Capital, RA Capital Management & 19 others	70/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	70/100
1710th	Proteovant Therapeutics 2021, King Of Prussia (United States), Acquired	Developer of targeted protein degrader therapies for cancer and hematology	-	-	26/100